28 August 2018 - Grünenthal announced that the European Commission has followed the positive opinion of the CHMP and granted Duzallo marketing authorisation for the EU/EEA. 

Duzallo is a fixed-dose combination therapy that combines allopurinol and lesinurad. It is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years.

The marketing authorization has been granted for the 28 European Union member states, as well as for the EEA countries Norway, Iceland and Liechtenstein. The approval by the European Commission is based on the positive opinion adopted by the CHMP of the EMA in June 2018.

Read Grunenthal press release